ELITE CONTROLLERS and lessons learned for HIV-1 cure.

Lopez-Galindez, C[1*], Pernas M; Casado C; Olivares I and Lorenzo-Redondo, R[2]

1. Virología Molecular. Laboratorio de Referencia e Investigación en Retrovirus. Centro Nacional de Microbiología. Instituto de Salud Carlos III. Majadahonda. Madrid

2. Division of Infectious Diseases, Northwestern University Feinberg School of Medicine, Chicago, Illinois 60011, USA

*:Corresponding author: Dr Cecilio López-Galíndez, Virología Molecular. Laboratorio de Referencia e Investigación en Retrovirus. Centro Nacional de Microbiología. Instituto de Salud Carlos III. Majadahonda. Madrid. SPAIN. Tlfno: 34 91 822 3918, Fax: 34 91 5097919, e-mail: clopez@isciii.es

Words. 2521

ABSTRACT

Following the success of HIV-1 antiviral treatment that maintains undetectable levels of viral replication and lack of clinical progression, the design of an HIV-1 cure for patients became the next objective. The success of the treated individuals and of subjects that spontaneously control the clinical progression for long periods, such as long term non progressors (LTNPs) and particularly LTNP Elite Controller (LTNP EC) have shed hope for the feasibility of a potential cure. Although a successful cure has not been attained yet, these patients have provided critical information on the mechanisms involved in this clinical control such as several host genetic factors as well as strong immune responses against the virus. Less attention has been applied to virological factors, particularly into the genetic variability of viruses and the consequences of viral evolution for the control of viral infection. Based on all these studies, it has become clear that a combination of several host, immune and viral factors is needed for the achievement of the control of viral replication and the non progressor clinical phenotype. As HIV-1 cure has been shown to be extremely difficult, a more feasible objective is the functional cure of the viral infection. After the analysis of several studies on the mechanisms of control in LTNP EC, we propose that some individuals with several host protective factors and with a prolonged viral control (>30 years), stable levels of CD4+ cells (>400-500 cells/μl) and without any sign of clinical progression could have attained a functional cure of the HIV-1 infection.

INTRODUCTION

The application of new and more potent antiretrovirals and novel drug combinations has permitted the control of the HIV-1 epidemic in the developed world. The combination of drugs in the active antiretroviral therapy (cART) attains, in the treated patients, durable suppression of HIV-1 viremia. The control of viral production in cART patients led to the proposal for the development of a potential cure of the HIV-1 infection [1]. Such cure, or sterilizing cure, would imply the permanent control of viral replication and the complete elimination of the virus from the body [1]. The elimination has been shown to be extremely difficult because viral reservoirs persist even under successful antiretroviral treatment. These remaining viral population in the reservoir constitute the principal burden for an effective HIV-1 cure, as they are the origin of a rapid rebound in viremia when treatment fails or is discontinued. Several strategies have been followed for the elimination of the HIV-1 reservoir without significant success. The majority of these strategies have focused on the reduction of the size of the viral cellular reservoir by the use of latency reactivating agents (LRA) as single agents or in combinations [2,3]. However, at present these treatments have not produced a significant decrease in the reservoir [2].

The sterilizing cure has only been reported in two individuals, the Berlin and the London patients [3,4]. These cases, however, have followed extremely difficult approaches that are not feasible for their implementation for the majority of the infected individuals. A less stringent objective, known as functional cure, consists in the permanent suppression of HIV-1 viral replication, in the absence of antiviral therapy, but without the need of viral eradication [5]. A situation resembling the functional cure is found among a minor group of HIV-1 patients, designated long-

term non-progressors (LTNP) that control the viral infection and the clinical progression spontaneously for long periods. Within LTNPs, there is a subgroup called LTNP elite controllers (LTNP EC) that on top of this control maintain undetectable viral loads for long periods [6]. These individuals have been extensively used for the investigation of the mechanisms involved in the control of the infection and they are considered a model for a functional cure of HIV-1 infection [7].

Definitions and characteristics of the LTNPS and LTNP EC patients

The studies performed with HIV-1 non-progressor (NP) patients have faced the problem relating the disparity of names and criteria used by the different groups in its definitions. These patients have been classified as NP patients, long-term HIV-1 positive (HLP), LTNP, or long-term survivors (LTS). Definitions were based in clinical and/or diagnostic criteria and years of follow-up. With the application of the viral load quantification (VL) in the patient´s follow-up, distinct designations were again established such as elite suppressors (ES), HIV-1 controllers (HIC) or Elite Controllers (EC). The different nomenclatures and criteria used in the definition of NP are summarized in [8]. For the characterization of the LTNP EC individuals, in a comprehensive definition, we propose the following: subjects who, in the absence of AIDS-related conditions and antiretroviral treatment, show HIV-1 infection for more than 10 years, stable CD4+ lymphocyte counts (>500 cells/µl) and undetectable viral loads (< 50 cp/ml)[6].

Multiple works were undertaken for the investigation of the causes of the viral infection control and the lack of clinical progression. The biomarkers involved in

the clinical non-progressor phenotype are related to three main areas, those related to the host, those to the immunological response and those to viral factors.

Host factors

The first factors that were associated to the viral control in LTNPs were certain HLA alleles particularly the HLA B57*, B58* and B27* because of their over representation in the NP patients [9]. Others genotypes of the CCR5, CCR2, SDF1 and the KIR3DS1 genes were later connected with non-progression [10]. Genome wide association studies detected other polymorphisms like the rs 9039999 SNP in the HLA C promoter and they further confirmed the above HLA alleles [10,11]. The important role for the HIV control of the class I HLA peptide presentation was also described [11]. However, the contribution of these host markers to differences in the viral load is limited and it was established to be at the 13-22% [12].

One of the most significant host factors associated with viral control is the 32 bp deletion in the CCR5 gene (Δ32-CCR5 genotype). This genotype was associated with the LTNP phenotype because of a significantly higher proportion of heterozygous for the deletion in LTNPs as confirmed in many cohorts [13]. Another example of host genes implicated in the NP phenotype is the FOXO3a gene that is linked to the persistence of memory CD4+ cells, particularly in the EC individuals, and to the loss of memory B cells [14].

Factors related to the immune response

Several studies demonstrated that viral control in LTNPs is strongly correlated with the cellular response [15] because of a tight association between Gag-specific cytotoxic CD4+ and CD8+ T lymphocyte responses, with a high poly functionality, and viral control [16-18]. Moreover, CD8+ T cells from HIV-1 controllers exhibit a potent capacity to suppress viral infection "*ex vivo"* [18]. These individuals also display a peculiar cytotoxic T lymphocyte activation phenotype [19]. Although there are reports suggesting that the maintenance of memory B cells and a broad neutralizing capacity may contribute to the natural control of HIV-1 infection [20], the humoral response and, in particular, the neutralizing antibodies does not play an important role in the controller phenotype [21].

Virological factors

LTNP EC individuals display very low levels of virus and nucleic acids [22]. There is an ongoing debate about the characteristics of the viruses prevailing in LTNPs patients.

Defective viruses

In general, viruses from NP show low fitness and replication capacity, or are defective in some of the viral proteins. The first characterization of defective viruses in non-progressors patients was in the Australian blood donor cohort which presented viruses with important deletions in *nef* gene [23]. Deletions in *nef* gene were also found in viruses from other studies [24]. Inactivating insertions or mutations producing the truncation of *gag* and *pol* gene proteins or Vpr, Vif, Vpu generated defective viruses described in isolates from LTS or LTNPs [25]

also reviewed in [13]. In our group, we found a significant association between the lack of viral replication of the viruses from LTNP and the major presence of large genomic deletions in different genomic regions [26].

Deleterious or attenuated viruses

Several studies established the low viral replication capacity of viruses from LTS, LTNP and EC. The causes of such low replication capacity or viral fitness of these viruses were investigated and, in some cases, explained by the presence of CTL escape mutations in Gag proteins. Some of these mutants confer a low fitness to the virus [27]. In addition, recombinant viruses with reverse transcriptase-integrase sequences from HIV-1 EC showed a reduced replication capacity [28].

Other reports focused on the phenotypic role of the viral envelope. Lassen et al characterized the viral envelopes from a group of ES showing a significant decreased entry efficiency and a slow kinetic of the binding which contributed to the clinical ES phenotype [29]. Also an envelope with an unusual length in the V1 which conferred escape from monoclonal antibodies of the V3-glycan class was found in an elite controller [30]. In a study from our group, we analyzed the viral characteristics of the envelopes from a cluster of LTNP EC individuals with lack of clinical progression for more than 20 years. We established that these envelopes had a very low affinity for the CD4 molecule and a low transfer activity. These characteristics produced a very low cellular signaling within the host cell. These viral properties helped in the explanation of the low transmissibility and replication capacity of these viruses possibly and the patient´s LTNP EC phenotype [31].

In contrast, Blankson et al isolated viruses from elite suppressors (ES) with replicating characteristics similar to those of progressor patients [32]. This work established that the virus was not responsible for the non-progressor phenotype in ES. However, this result cannot be generalized because the virus was isolated in only four of the 10 patients studied. The replicative capacity of viruses from ES was also confirmed in an "*ex vivo*" humanized mouse model and also supporting the role of host factors in the viral control [33,34].

However even if these individuals are infected with replicative viruses, these viruses could become deleterious because of the pressure of the host and immune system [7]. In summary, after reviewing all the virological studies, we can conclude that many LTNP EC show either no replicating virus, deleterious viruses or viruses with important defects. These alterations in the viruses result in low fitness and low replication capacity [35] with an important effect on the LTNP EC phenotype. We propose, that these deleterious or attenuated viruses are a necessary component in the combinations of factors required for the control in LTNP EC.

Combination of factors

From the investigations carried out in LTNP EC many important conclusions can be derived. The control of viral replication in LTNP EC has been associated, in multiple studies, with different markers. Combined genotypes of CCR5, CCR2, SDF1, and HLA genes can predict the long-term non-progressor status in HIV-1 infected individuals. In a systematic work from our group carried out with HIV-1 patients with distinct progression rates, we disclosed that there was a progressive

accumulation of viral and host factors from rapid, to standard progressor, LTNP viremic and LTNP EC. This work clearly demonstrated that is was necessary a combination of several host and virologic factors to achieve the extreme LTNP EC phenotype [6], as demonstrated in other studies [15,36,37].

As a consequence of this multifactorial response and the different contribution of the distinct factors to the infection control, the group of LTNP EC is not homogenous. There are reports of LTNP EC that control viral replication without known host markers [38], or without known host HLA alleles [39]. Also, our group demonstrated that a combination of non-replicating viruses and a strong antiviral immune response explained the non-progressor phenotype in a super infected HIV individual [36]. A general lesson from the LTNP EC studies is that the achievement of a complete control of the infection cannot be explained by a single factor, but requires a combination of factors [37,43].

Genetic variability of viral populations in LTNP EC

HIV-1 replication is characterized by the generation of a high genetic diversity. This is due to the inaccuracy of the reverse transcriptase that lacks proofreading activity [40]. Thus, viral replication results in diverse viral population best described as viral quasispecies [41,42]. Not only the genetic diversity of the HIV-1 populations, but also the size of the populations, have consequences for viral fitness and pathogenesis [44,45]. From genetic studies, it is known that small populations are prone to fitness losses because of the irreversible accumulation of deleterious mutations as previously described "*in vitro*" [41], due to the operation of the Muller´s ratchet. In contrast, large viral populations result in

fitness gains [42]. LTNPs and LTNP EC show low or undetectable viral populations sizes and, thus, are susceptible to the Muller effect [20,24,33].

In addition, the correlation between genetic variability and viral fitness has been established and was experimentally demonstrated with HIV-1 "*in vitro*" studies [43]. The association between viral diversity and pathogenesis was described in HIV-1 patients with different clinical progression [47,48]. In a work of our group with 14 LTNPs (CD4+>500, 10 years), individuals without a complete control of viral replication showed some degree viral evolution, whereas those with lower viral load showed absence of viral evolution; this study defined a viral load threshold for viral evolution [43]. Very different patterns of viral genetic diversity were found among HIV controllers [44] and two super infected HIV controllers showed the complete control of viral evolution [45]. In another study of our group with a cohort of EC controllers, individuals who showed a persistent control of viral replication displayed extremely low genetic diversity whereas EC with a transient control displayed a certain degree of viral diversity [15], thus supporting the role of viral diversity in viral evolution and pathogenesis [46].

Analysis of genetic variability in viruses from distinct groups of patients.

To complement these studies on viral genetic variability, we decided to compare the quasispecies heterogeneity in viral populations from different groups of individuals with a controlled infection, patients under cART, LTNPs and the group of Elite Controllers with a transient or a permanent control [15]. We performed this analysis taking advantage of sequences deposited in the HIV Database. Although both, LTNPs EC and ART treated patients maintain undetectable viral

loads during many years of infection, genetic diversity among them is different. As shown in Figure 1, LTNP EC patients displayed an extremely low genetic diversity, the lowest diversity of all the patients analyzed, and was lower than the cART patients. Moreover, the genetic diversity remained constant during the infection. In contrast, in patients where there is evidence of viral replication like viremic LTNPs and transient EC, the genetic diversity differed widely among them, and more remarkably, it changed during the patients' follow-up.

Some of the LTNP EC patients analyzed are subjects infected for more than 25 years with no signs of clinical progression [29, 34]. In this group of individuals, even if residual replicating viruses still persist, we hypothesize that the low genetic diversity and low viral population size will make very improbable or even impossible the fitness recovery. This hypothesis is based on our previous "*in vitro*" study on Muller's ratchet, which establishes that quasispecies of HIV-1 with low diversity and low population size accumulate, during replication, harmful mutations that irreversibly leads to extinction [52].

The analysis of viral genetic diversity could be a very useful biomarker for the identification of individuals, mainly in the LTNP and LTNP EC, with a strong and prolonged control of viral replication and no evolution. The LTNP EC individuals with these characteristics are good candidates for a functional cure of the HIV-1 infection. Thus, the genetic variability could be a good prognostic marker of viral control and a surrogate of HIV-1 functional cure.

A lesson that could be derived from these studies on genetic diversity is that if you attain a small viral population size and a low viral diversity, even with some replicating virus remaining in the individual, the virus will not be able to recover viral fitness.

CONCLUSIONS.

The eradication of the HIV-1 virus from all the different body compartments is extremely difficult and thus far is not practicable as a general strategy for the control of the HIV-1 epidemic. A less ambitious objective, the functional cure of HIV-1 infection seems to be a more practical and feasible solution. As, the functional cure has not been yet defined, we propose the following characterization: individuals with several protective host markers, prolonged viral control (>30 years and no viral evolution), stable levels of CD4+ cells (>400-500 cells/µl) (because of strong immune responses) and without any sign of clinical progression. Perhaps there are individuals fulfilling these criteria, mostly within the LTNP EC cohort, that could have already attained the functional cure of the HIV-1 infection.

Financial Support:

Work in the VM group in the ISCIII was supported by grants SAF (2010-17226) and (2016-77894-R) from MINECO (Spain) and FIS (PI 13/02269, ISCIII) and in part by the RIS-RETIC grants RD06/006/0036 and RD12/0017/0028 funded by the ISC III-FEDER. MP has a contract of RIS-RETIC RD12/0017/0036. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Figure Legend.

FIGURE 1. Estimates of average evolutionary diversity over sequence pairs within individual and time point. The number of base differences per site (P-Distance) from averaging over all sequence pairs within each time point analyzed for every individual are shown. Standard error estimates are shown for each data point and were obtained by a bootstrap procedure (500 replicates). Values are colored according to the individual's clinical group. We included infected individuals under cART [49], LTNPs [43], and Transient "Elite Controllers" [15] to compare to the viral populations from the LTNP "Elite Controllers" [15]. Most of the individuals had multiple time points available.